In this regard, Rusak et al. [115] developed a marker panel for B cells (CD19+, CD20+, CD22+, and CD79a+), T cells (CD3+/CD4+/CD5+/CD8+), and Treg cells (CD4+/CD25+++/Foxp3high) to determine their absolute counts and correlate such information for the prognostication of newly diagnosed DLBCL patients. Here, CD8A is linked to diffuse large B-cell lymphoma.